Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates

Sarfraz Saleemi

Overview

The Saudi Association for Pulmonary Hypertension (previously called Saudi Advisory Group for Pulmonary Hypertension) has published the first Saudi Guidelines on Diagnosis and Treatment of Pulmonary Arterial Hypertension back in 2008. [1] That guideline was very detailed and extensive and reviewed most aspects of pulmonary hypertension (PH). One of the disadvantages of such detailed guidelines is the difficulty that some of the readers who just want to get a quick guidance or looking for a specific piece of information might face. All efforts were made to develop this guideline in an easy-to-read form, making it very handy and helpful to clinicians dealing with PH patients to select the best management strategies for the typical patient suffering from a specific condition. This Guideline was designed to provide recommendations for problems frequently encountered by practicing clinicians involved in management of PH. This publication targets mainly adult and pediatric PH-treating physicians, but can also be used by other physicians interested in PH.

Summary

Comprehensive PH guidelines

Author Comments

Sarfraz Saleemi, MD,MRCP,FCCP
Sarfraz Saleemi, MD,MRCP,FCCP
King Faisal Specialist Hospital and Research Centre
Dr
Pulmonary Hypertension
Riyadh, Riyadh | Saudi Arabia
The guidelines are being updated Sarfraz Saleemi, MD,MRCP,FCCP

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia.

Authors:
Sarfraz Saleemi, MD,MRCP,FCCP
Sarfraz Saleemi, MD,MRCP,FCCP
King Faisal Specialist Hospital and Research Centre
Dr
Pulmonary Hypertension
Riyadh, Riyadh | Saudi Arabia

Ann Thorac Med 2014 Jul;9(Suppl 1):S67-73

Department of Medicine, Division of Pulmonary Medicine, King Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.

Hereditary hemoglobin disorders affecting the globin chain synthesis namely thalassemia syndromes and sickle cell disease (SCD) are the most common genetic disorders in human. Around 7% of the world population carries genes for these disorders, mainly the Mediterranean Basin, Middle and Far East, and Sub-Saharan Africa. An estimated 30 million people worldwide are living with sickle cell disease, while 60-80 million carry beta thalassemia trait. About 400,000 children are born with severe hemoglobinopathies each year. Cardiovascular complications of hemoglobinopathies include left and right ventricular (RV) dysfunction, arrhythmias, pericarditis, myocarditis, valvular heart disease, myocardial ischemia, and notably pulmonary hypertension (PH). Because of a unique pathophysiology, pulmonary hypertension associated with hemolytic disorders was moved from WHO group I to group V PH diseases. Treatment strategies are also unique and include blood transfusion, iron chelation, hydroxyurea, and oxygen therapy. The role of PH-specific agents has not been established.

Download full-text PDF

Source
http://dx.doi.org/10.4103/1817-1737.134039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114267PMC
July 2014
76 Reads

Publication Analysis

Top Keywords

pulmonary hypertension
16
hypertension associated
8
sickle cell
8
cell disease
8
associated hemolytic
8
disease myocardial
4
group diseases
4
60-80 carry
4
diseases treatment
4
disease 60-80
4
mediterranean basin
4
carry beta
4
trait 400000
4
group group
4
thalassemia trait
4
beta thalassemia
4
living sickle
4
worldwide living
4
middle east
4
unique include
4

Similar Publications